Search research articles
Contact Us
Filters
Showing results (121-130 of 212) with videos related to
Page
of 22
Sort By:
Pediatric Blood & Cancer
|
April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
John M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer
|
July 9, 2015
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma
Clarke P Anderson, Katherine K Matthay, John P Perentesis, et al.
Pediatric Blood & Cancer
|
May 7, 2009
Initial testing of aplidin by the pediatric pre-clinical testing program
Christopher L Morton, Peter J Houghton, Richard Gorlick, et al.
Cancer Chemotherapy and Pharmacology
|
January 10, 2021
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors
Jacob S Thomas, Anthony B El-Khoueiry, Barry J Maurer, et al.
Cell Death & Disease
|
May 16, 2020
MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma
Sung-Jen Wei, Thinh H Nguyen, In-Hyoung Yang, et al.
Pediatric Blood & Cancer
|
July 31, 2010
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program
Stephen T Keir, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer
|
February 8, 2011
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program
E Anders Kolb, Richard Gorlick, Richard Lock, et al.
Pediatric Blood & Cancer
|
May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program
Nino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer
|
November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling
E Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer
|
October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program
Raushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Page
of 22
Search research articles
Search
Showing results (121-130 of 212) with videos related to
Sort By:
Page
of 22
Pediatric Blood & Cancer
|
April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
John M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer
|
July 9, 2015
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma
Clarke P Anderson, Katherine K Matthay, John P Perentesis, et al.
Pediatric Blood & Cancer
|
May 7, 2009
Initial testing of aplidin by the pediatric pre-clinical testing program
Christopher L Morton, Peter J Houghton, Richard Gorlick, et al.
Cancer Chemotherapy and Pharmacology
|
January 10, 2021
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors
Jacob S Thomas, Anthony B El-Khoueiry, Barry J Maurer, et al.
Cell Death & Disease
|
May 16, 2020
MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma
Sung-Jen Wei, Thinh H Nguyen, In-Hyoung Yang, et al.
Pediatric Blood & Cancer
|
July 31, 2010
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program
Stephen T Keir, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer
|
February 8, 2011
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program
E Anders Kolb, Richard Gorlick, Richard Lock, et al.
Pediatric Blood & Cancer
|
May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program
Nino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer
|
November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling
E Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer
|
October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program
Raushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Page
of 22